Biodegradable Ultrasmall-in-Nano Architectures Loaded with Cisplatin Prodrug in Combination with Ionizing Radiation Induces DNA Damage and Apoptosis in Pancreatic Ductal Adenocarcinoma
Authors:
- Pei Pei ChePCPei Pei Che
- Ana Katrina MapanaoAMAna Katrina Mapanao
- Alessandro GregoriAlessandro Gregori
- Maria Laura ErminiMEMaria Laura Ermini
- Agata ZamborlinAZAgata Zamborlin
- Mjriam CapulaMCMjriam Capula
- Danitsja NgadiminDNDanitsja Ngadimin
- Ben J. SlotmanBSBen J. Slotman
- Valerio VolianiValerio Voliani
- Peter SminiaPSPeter Sminia
- Elisa GiovannettiElisa Giovannetti
Open Access
Abstract
Considering the dismal survival rate, novel therapeutic strategies are warranted to improve the outcome of pancreatic ductal adenocarcinoma (PDAC). Combining nanotechnology for delivery of chemotherapeutics—preferably radiosensitizing agents—is a promising approach to enhance the therapeutic efficacy of chemoradiation. We assessed the effect of biodegradable ultrasmall-in-nano architectures (NAs) containing gold ultra-small nanoparticles (USNPs) enclosed in silica shells loaded with cisplatin prodrug (NAs-cisPt) combined with ionizing radiation (IR). The cytotoxic effects and DNA damage induction were evaluated in PDAC cell lines (MIA PaCa2, SUIT2-028) and primary culture (PDAC3) in vitro and in the chorioallantoic membrane (CAM) in ovo model. Unlike NAs, NAs-cisPt affected the cell viability in MIA PaCa2 and SUIT2-028 cells. Furthermore, NAs-cisPt showed increased γH2AX expression up to 24 h post-IR and reduced β-globin amplifications resulting in apoptosis induction at DNA and protein levels. Similarly, combined treatment of NAs-cisPt + IR in PDAC3 and SUIT2-028 CAM models showed enhanced DNA damage and apoptosis leading to tumor growth delay. Our results demonstrate an increased cytotoxic effect of NAs-cisPt, particularly through its release of the cisplatin prodrug. As cisplatin is a well-known radiosensitizer, administration of cisplatin prodrug in a controlled fashion through encapsulation is a promising new treatment approach which merits further investigation in combination with other radiosensitizing agents.Keywords
Funding Information
- ZABAWAS Foundation (CCA 2019-5-55, Project #2006784, 11957, AIRC/IG-grant 24444, AIRC/MFAG 19852)
- Cancer Center Amsterdam (CCA 2019-5-55, Project #2006784, 11957, AIRC/IG-grant 24444, AIRC/MFAG 19852)
- KWF Kankerbestrijding (CCA 2019-5-55, Project #2006784, 11957, AIRC/IG-grant 24444, AIRC/MFAG 19852)
- Associazione Italiana per la Ricerca sul Cancro (CCA 2019-5-55, Project #2006784, 11957, AIRC/IG-grant 24444, AIRC/MFAG 19852)
This publication has 54 references indexed in Scilit:
- Deciphering the role of the ERCC2 gene polymorphism on anticancer drug sensitivityCarcinogenesis, 2012
- Gold nanoparticles in cancer therapyActa Pharmacologica Sinica, 2011
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerNew England Journal of Medicine, 2011
- NPRL2 Sensitizes Human Non-Small Cell Lung Cancer (NSCLC) Cells to Cisplatin Treatment by Regulating Key Components in the DNA Repair PathwayPLOS ONE, 2010
- Toxicity and cellular uptake of gold nanoparticles: what we have learned so far?Journal of Nanoparticle Research, 2010
- DNA-PKcs plays a dominant role in the regulation of H2AX phosphorylation in response to DNA damage and cell cycle progressionBMC Molecular Biology, 2010
- Mitaplatin, a potent fusion of cisplatin and the orphan drug dichloroacetateProceedings of the National Academy of Sciences, 2009
- Polyvalent Oligonucleotide Gold Nanoparticle Conjugates as Delivery Vehicles for Platinum(IV) WarheadsJournal of the American Chemical Society, 2009
- Kinetics of H2AX phosphorylation after exposure to cisplatinCytometry Part B: Clinical Cytometry, 2008
- Structure of the DNA Repair Helicase XPDCell, 2008